Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 12/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56867 | 1.00 | CYP11B2 (0.53) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL15744302 | 0.86 | DGAT1 (0.41) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL18285726 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL5361521 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL29988758 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL415598 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL690073 | 0.81 | PTPN7 (0.47) | CYP11B2CYP11B1KDM1ADGAT1 | |
| SCHEMBL29890371 | 0.81 | PTPN7 (0.47) | CYP11B2CYP11B1KDM1ADGAT1 | |
| SCHEMBL6267032 | 0.80 | KDM1A (0.50) | CYP11B2CYP11B1KDM1A | |
| SCHEMBL30864218 | 0.80 | KDM1A (0.50) | CYP11B2CYP11B1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743085-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4713327-A1 | SPIRO DERIVATIVES AS WRN INHIBITORS | Insilico Medicine IP Limited (HK) | 2026-03-25 | — | — | EP | disclosed |
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4634161-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-120152972-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025119195-A1 | COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4237404-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| CN-111315744-B | Heteroaryl tetrahydropyridine compound, preparation method, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023063301-A1 | METHOD FOR PRODUCING FLUORINATED AROMATIC COMPOUND | ダイキン工業株式会社 | 2023-04-20 | — | — | WO | disclosed |
| WO-2022269251-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-12-29 | — | — | WO | disclosed |
| CN-114846015-A | Substituted heteroaryl compounds useful as T cell activators | 百时美施贵宝公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-110857298-B | Heteroaryl tetrahydropyridines, pharmaceutical compositions containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022090724-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |